Lennar Edges Higher;Verve Therapeutics Soars; T-Mobile Slides | Stock Movers
June 17, 2025
521
2
0.38%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Bloomberg Podcasts Episodes Around June 17, 2025
See what was published immediately before and after this episode.
2:22Iran Regime 'On the Verge of Collapse' as Conflict with Israel Continues
12:00ICYMI: Facial Recognition vs Facial Verification | Bloomberg Businessweek
4:43Now PlayingLennar Edges Higher;Verve Therapeutics Soars; T-Mobile Slides | Stock Movers
YouTube Description
as posted by the channelOn this episode of Stock Movers:
- Lennar (LEN) is edging higher after a miss on the homebuilder’s new orders outlook was tempered by better-than-expected gross margins, which RBC Capital Markets said should reassure investors. Analysts including Mike Dahl say Lennar’s results came in better than feared on gross margin percentage with orders modestly missing, while the guide for a flat quarter-on-quarter gross margin percentage also surprised on the upside. Lennar’s second-quarter adjusted earning per share missed consensus estimates with higher selling, general, and administrative expenses and lower average selling price, but gross margins in-line, write analysts including Matthew Bouley of Barclays.
- Sunrun (RUN) shares are sinking in the premarket. It comes as KeyBanc Capital Markets analyst Sophie Karp cut the recommendation on Sunrun Inc. to underweight from sector weight. Investors who followed Karp's recommendation received a 0% return in the past year, compared with a negative 27% return on the shares.
- Verve Therapeutics (VERV) is soaring following a Financial Times report that Eli Lilly is reportedly in advanced talks to buy the gene-editing startup for as much as $1.3 billion. Eli Lilly (LLY) is lower on M&A news. Eli Lilly would pay almost $1 billion upfront and another $300 million based on Verve reaching clinical milestones, according to FT.
- T-Mobile (TMUS) is sliding this morning after a report that SoftBank raised around $4.8 billion through a sale of 21.5 million T-Mobile US Inc. shares at $224 each. The deal represents a 3% discount to T-Mobile US's Monday closing price of $230.99 per share and is the biggest US share sale since February.
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
Lennar Edges Higher;Verve Therapeutics Soars; T-Mobile Slides
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.